Satellos
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Bay St Suite 2800, Toronto, Ontario,...Phone Number
(647) 660-1780Website
www.satellos.comRevenue
-Stock Symbol
MSCLFIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Satellos
Satellos is dedicated to improving the treatment of Duchenne muscular dystrophy and other muscle diseases by developing small molecule therapeutics that restore the body's ability to regenerate muscle. Their innovative MyoReGenX platform focuses on reactivating the natural repair processes disrupted by the absence of dystrophin. The company targets AAK1, a protein crucial for guiding muscle stem cells in tissue repair. Satellos aims to enhance outcomes for individuals affected by degenerative muscle conditions through their research and therapeutic advancements.Explore more
Satellos Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Satellos your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Satellos had a recent Job posting/layoffs
Check if Satellos has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Satellos has new funding data
Satellos, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Satellos is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Satellos
Product Launch: Get notified when Satellos launches new products
Earning: See what the market has to say on Satellos recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Satellos
Compare insights from companies similar to Satellos, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Satellos is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Satellos is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Satellos.
Satellos financials insights
Gather financial insights about Satellos, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Corporate Investment
$1M
2024
Other Financing Round
$40M
Satellos Tech Stack
A closer look at the technologies used by Satellos
Most Recent Scoops
Event
Retail/Store Systems, Product Marketing, Events, Sales, Software, Store Operations, Logistics / Supply Chain, Food & Beverage, Field Marketing, Operations
Person-Based
Earnings, Medical Research, Pharmaceuticals, Finance
Open Position
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Satellos News & Media
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results for the second quarter ended June 30, 2026. The company also provided an update on the clinical development program for SAT-3247, an orally administered, small molecule drug candidate designed to restore muscle regeneration in people living with DuchenneDeborah D. Ascheim, M.D. Elected to Longeveron Board of Directors | INN
XHV2fwLHHnjGOVt4U0kEl6wYUwgnBmPtwDbJ-2zEpqlqQJ6s33Xx8cjk6C8OTDu7-U=" target="_blank" rel="nofollow">Longeveron Inc. a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer ...Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced six-month interim data from TRAILHEAD evaluating its investigational drug candidate SAT-3247 in adults living with Duchenne muscular dystrophy ("Duchenne" or "DMD").Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Satellos
Sign Up For FreeTo access detailed company insights
Satellos is dedicated to improving the treatment of Duchenne muscular dystrophy and other muscle diseases by developing small molecule therapeutics that restore the body's ability to regenerate muscle. Their innovative MyoReGenX platform focuses on reactivating the natural repair processes disrupted by the absence of dystrophin. The company targets... Read More
